Patients with AML-MRC benefit from decitabine in combination with low-dose G-CSF, cytarabine and aclarubicin: A single center cohort study
Patients with acute myeloid leukemia with myelodysplasia-related changes (AML-MRC) are insensitive to conventional chemotherapy and, therefore, have a poor prognosis. To evaluate the clinical efficacy and safety of low-dose decitabine in combination with small-dose CAG regimen (D-CAG regimen) in tre...
保存先:
| 主要な著者: | , , , , , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Elsevier
2022-01-01
|
| シリーズ: | Leukemia Research Reports |
| 主題: | |
| オンライン･アクセス: | http://www.sciencedirect.com/science/article/pii/S2213048922000668 |
| タグ: |
タグなし, このレコードへの初めてのタグを付けませんか!
|